Switch to:
Also traded in: Germany, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 231.24
GWPH's Cash-to-Debt is ranked higher than
71% of the 859 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.03 vs. GWPH: 231.24 )
Ranked among companies with meaningful Cash-to-Debt only.
GWPH' s Cash-to-Debt Range Over the Past 10 Years
Min: 18.99  Med: 548.24 Max: No Debt
Current: 231.24
18.99
No Debt
Equity-to-Asset 0.85
GWPH's Equity-to-Asset is ranked higher than
87% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. GWPH: 0.85 )
Ranked among companies with meaningful Equity-to-Asset only.
GWPH' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.07  Med: 0.6 Max: 0.9
Current: 0.85
-0.07
0.9
Debt-to-EBITDA -0.01
GWPH's Debt-to-EBITDA is ranked lower than
99.99% of the 495 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.92 vs. GWPH: -0.01 )
Ranked among companies with meaningful Debt-to-EBITDA only.
GWPH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.22  Med: -0.01 Max: 0.05
Current: -0.01
-0.22
0.05
Piotroski F-Score: 5
Altman Z-Score: 16.08
Beneish M-Score: -2.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -2267.41
GWPH's Operating Margin % is ranked lower than
95% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.97 vs. GWPH: -2267.41 )
Ranked among companies with meaningful Operating Margin % only.
GWPH' s Operating Margin % Range Over the Past 10 Years
Min: -2267.41  Med: -56.74 Max: 14.66
Current: -2267.41
-2267.41
14.66
Net Margin % -2317.38
GWPH's Net Margin % is ranked lower than
94% of the 802 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.32 vs. GWPH: -2317.38 )
Ranked among companies with meaningful Net Margin % only.
GWPH' s Net Margin % Range Over the Past 10 Years
Min: -2317.38  Med: -32.73 Max: 15.13
Current: -2317.38
-2317.38
15.13
ROE % -61.50
GWPH's ROE % is ranked lower than
83% of the 832 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.94 vs. GWPH: -61.50 )
Ranked among companies with meaningful ROE % only.
GWPH' s ROE % Range Over the Past 10 Years
Min: -75.15  Med: -15.59 Max: 60.26
Current: -61.5
-75.15
60.26
ROA % -53.73
GWPH's ROA % is ranked lower than
85% of the 871 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. GWPH: -53.73 )
Ranked among companies with meaningful ROA % only.
GWPH' s ROA % Range Over the Past 10 Years
Min: -64.08  Med: -10.27 Max: 14.64
Current: -53.73
-64.08
14.64
ROC (Joel Greenblatt) % -437.19
GWPH's ROC (Joel Greenblatt) % is ranked lower than
87% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.23 vs. GWPH: -437.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GWPH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -437.19  Med: -218.48 Max: 269.39
Current: -437.19
-437.19
269.39
3-Year Revenue Growth Rate -31.70
GWPH's 3-Year Revenue Growth Rate is ranked lower than
95% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. GWPH: -31.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GWPH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -25.65 Max: 126.3
Current: -31.7
0
126.3
3-Year EBITDA Growth Rate -54.90
GWPH's 3-Year EBITDA Growth Rate is ranked lower than
98% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. GWPH: -54.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GWPH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -58.1 Max: 12.8
Current: -54.9
0
12.8
3-Year EPS without NRI Growth Rate -100.00
GWPH's 3-Year EPS without NRI Growth Rate is ranked lower than
98% of the 663 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. GWPH: -100.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GWPH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: 16.7
Current: -100
0
16.7
GuruFocus has detected 4 Warning Signs with GW Pharmaceuticals PLC GWPH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GWPH's 30-Y Financials

Financials (Next Earnings Date: 2019-02-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

GWPH Guru Trades in Q4 2017

Jim Simons 16,820 sh (New)
Pioneer Investments 500 sh (New)
Leon Cooperman 30,000 sh (New)
Steven Cohen 401,665 sh (+153.67%)
Louis Moore Bacon 20,000 sh (+100.00%)
Andreas Halvorsen 211,869 sh (-69.90%)
» More
Q1 2018

GWPH Guru Trades in Q1 2018

Pioneer Investments 1,300 sh (+160.00%)
Leon Cooperman 70,000 sh (+133.33%)
Andreas Halvorsen Sold Out
Jim Simons Sold Out
Steven Cohen 363,300 sh (-9.55%)
Louis Moore Bacon 10,000 sh (-50.00%)
» More
Q2 2018

GWPH Guru Trades in Q2 2018

Jim Simons 106,800 sh (New)
Louis Moore Bacon 20,000 sh (+100.00%)
Pioneer Investments 1,500 sh (+15.38%)
Leon Cooperman Sold Out
Steven Cohen 141,100 sh (-61.16%)
» More
Q3 2018

GWPH Guru Trades in Q3 2018

Stanley Druckenmiller 62,100 sh (New)
Pioneer Investments 1,500 sh (unchged)
Louis Moore Bacon 20,000 sh (unchged)
Jim Simons 16,400 sh (-84.64%)
Steven Cohen 84,200 sh (-40.33%)
» More
» Details

Insider Trades

Latest Guru Trades with GWPH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major  
Compare:DHA:SQURPHARMA, SZSE:000591, XKRX:000100, SZSE:002262, SZSE:000989, XKRX:068760, SGX:H02, BOM:524816, BOM:500660, SZSE:002424, SHSE:600664, SHSE:600572, SHSE:600771, XSWX:COPN, NAS:AERI, BOM:530019, SHSE:600252, HKSE:01666, SZSE:300267, BOM:500488 » details
Traded in other countries:GW2.Germany, GWP.UK, GWPRF.USA,
Headquarter Location:UK
GW Pharmaceuticals PLC is engaged in the research, development and commercialisation of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant.

GW Pharmaceuticals PLC is a UK based company, engaged in the research, development, and commercialization of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. Its business activities are functioned through three reportable segments which are Commercial, Sativex Research and Development and Pipeline Research and Development. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.

Top Ranked Articles about GW Pharmaceuticals PLC

Breaking News: Expected Passage of 2018 Farm Bill on Monday Could Provide Opportunity to Gain Big in this Uncertain Market
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome
GW Pharmaceuticals to Report Fourth Quarter and Year-End Financial Results and Host Conference Call on 27 November, 2018
EPIDIOLEX® (cannabidiol) Oral Solution – the First FDA-approved Plant-derived Cannabinoid Medicine – Now Available by Prescription in the U.S.
GW Pharmaceuticals plc Announces the Closing of Public Offering of ADSs, Raising Gross Proceeds of $345 Million and Full Exercise of Underwriters' Option to Purchase Additional ADSs
GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $300 Million
GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $300 Million
GW Pharmaceuticals Announces Proposed Public Offering of ADSs
GW Pharmaceuticals plc and its U.S. Subsidiary Greenwich Biosciences Announce the DEA has Rescheduled EPIDIOLEX® (cannabidiol) Oral Solution to Schedule V
GW Pharmaceuticals to Report Third Quarter Financial Results and Host Conference Call on 7 August, 2018

Ratios

vs
industry
vs
history
PB Ratio 5.82
GWPH's PB Ratio is ranked lower than
75% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.64 vs. GWPH: 5.82 )
Ranked among companies with meaningful PB Ratio only.
GWPH' s PB Ratio Range Over the Past 10 Years
Min: 2.16  Med: 5.96 Max: 17.9
Current: 5.82
2.16
17.9
PS Ratio 191.02
GWPH's PS Ratio is ranked lower than
97% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. GWPH: 191.02 )
Ranked among companies with meaningful PS Ratio only.
GWPH' s PS Ratio Range Over the Past 10 Years
Min: 1.56  Med: 25.56 Max: 240
Current: 191.02
1.56
240
EV-to-EBIT -6.85
GWPH's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.85 vs. GWPH: -6.85 )
Ranked among companies with meaningful EV-to-EBIT only.
GWPH' s EV-to-EBIT Range Over the Past 10 Years
Min: -62.8  Med: -19.2 Max: 121.1
Current: -6.85
-62.8
121.1
EV-to-EBITDA -7.07
GWPH's EV-to-EBITDA is ranked lower than
99.99% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.24 vs. GWPH: -7.07 )
Ranked among companies with meaningful EV-to-EBITDA only.
GWPH' s EV-to-EBITDA Range Over the Past 10 Years
Min: -68.1  Med: -20.8 Max: 65.7
Current: -7.07
-68.1
65.7
EV-to-Revenue 156.31
GWPH's EV-to-Revenue is ranked lower than
94% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.24 vs. GWPH: 156.31 )
Ranked among companies with meaningful EV-to-Revenue only.
GWPH' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.7  Med: 21.4 Max: 201.2
Current: 156.31
0.7
201.2
Current Ratio 6.66
GWPH's Current Ratio is ranked higher than
89% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. GWPH: 6.66 )
Ranked among companies with meaningful Current Ratio only.
GWPH' s Current Ratio Range Over the Past 10 Years
Min: 1.75  Med: 5.59 Max: 15.11
Current: 6.66
1.75
15.11
Quick Ratio 6.33
GWPH's Quick Ratio is ranked higher than
90% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. GWPH: 6.33 )
Ranked among companies with meaningful Quick Ratio only.
GWPH' s Quick Ratio Range Over the Past 10 Years
Min: 1.7  Med: 5.59 Max: 15.11
Current: 6.33
1.7
15.11
Days Inventory 735.59
GWPH's Days Inventory is ranked lower than
98% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 119.80 vs. GWPH: 735.59 )
Ranked among companies with meaningful Days Inventory only.
GWPH' s Days Inventory Range Over the Past 10 Years
Min: 298.61  Med: 612.5 Max: 1172.52
Current: 735.59
298.61
1172.52
Days Sales Outstanding 60.82
GWPH's Days Sales Outstanding is ranked lower than
99% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 81.76 vs. GWPH: 60.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
GWPH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.95  Med: 8.33 Max: 60.82
Current: 60.82
1.95
60.82
Days Payable 593.98
GWPH's Days Payable is ranked higher than
98% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.32 vs. GWPH: 593.98 )
Ranked among companies with meaningful Days Payable only.
GWPH' s Days Payable Range Over the Past 10 Years
Min: 414.97  Med: 623.97 Max: 2076.2
Current: 593.98
414.97
2076.2

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 8.62
GWPH's Price-to-Net-Cash is ranked lower than
99.99% of the 277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.41 vs. GWPH: 8.62 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GWPH' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.16  Med: 8.77 Max: 33.33
Current: 8.62
2.16
33.33
Price-to-Net-Current-Asset-Value 7.68
GWPH's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 559 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.66 vs. GWPH: 7.68 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GWPH' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.03  Med: 7.18 Max: 25
Current: 7.68
2.03
25
Price-to-Tangible-Book 5.94
GWPH's Price-to-Tangible-Book is ranked lower than
66% of the 749 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.33 vs. GWPH: 5.94 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GWPH' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.99  Med: 6.75 Max: 157.5
Current: 5.94
1.99
157.5
Price-to-Median-PS-Value 7.44
GWPH's Price-to-Median-PS-Value is ranked lower than
99.99% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.94 vs. GWPH: 7.44 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GWPH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 1.15 Max: 8.83
Current: 7.44
0.14
8.83
Earnings Yield (Greenblatt) % -14.56
GWPH's Earnings Yield (Greenblatt) % is ranked lower than
85% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.31 vs. GWPH: -14.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GWPH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -28.8  Med: -2.9 Max: 6
Current: -14.56
-28.8
6

More Statistics

Revenue (TTM) (Mil) $13.24
EPS (TTM) $ -10.87
Beta3.97
Volatility49.40%
52-Week Range $105.12 - 179.65
Shares Outstanding (Mil)30.54 (ADR)

Analyst Estimate

Sep19
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.52
EPS without NRI ($) -0.52
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}